Vazouras K, Hsia Y, Folgori L, et al. - Researchers conducted this multicenter retrospective cohort study to describe the clinical presentation, treatment and outcomes of childhood urinary tract infection (UTI) caused by extended-spectrum beta-lactamase producing Εnterobacteriaceae (ESBL-PE) in Europe. Children 0 to 18 years of age with fever, positive urinalysis and positive urine culture for an ESBL-PE uropathogen, seen from January 2016 to July 2017 at a participating hospital, were included. Study participants included 142 children from 14 hospitals in 8 countries. After the end of treatment, recurrence of a UTI occurred 15.5 days (interquartile range, 9.0–19.0). Time to defervescence and clinical failure did not vary between initial microbiologically effective treatment/initial microbiologically ineffective treatment groups. For the empirical treatment of ESBL febrile UTIs, non-carbapenem beta-lactam antibiotics may be used before susceptibility testing results become available.